Secret Flamel drug snubbed by FDA; shares drop
This article was originally published in Scrip
Executive Summary
The new drug application (NDA) for a yet-to-be disclosed experimental medicine from French drug maker Flamel Technologies was rejected by the FDA, the company revealed on 29 April – news that had investors recoiling from the firm's shares.